Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Citação
OPEN HEART, v.5, n.2, article ID UNSP e000923, 9p, 2018
Resumo
Objectives The prognostic significance of transient use of inotropes has been sufficiently studied in recent heart failure (HF) populations. We hypothesised that risk stratification in these patients could contribute to patient selection for advanced therapies. Methods We analysed a prospective cohort of adult patients admitted with decompensated HF and ejection fraction (left ventricular ejection fraction (LVEF)) less than 50%. We explored the outcomes of patients requiring inotropic therapy during hospital admission and after discharge. Results The study included 737 patients, (64.0% male), with a median age of 58 years (IQR 48-66 years). Main aetiologies were dilated cardiomyopathy in 273 (37.0%) patients, ischaemic heart disease in 195 (26.5%) patients and Chagas disease in 163 (22.1%) patients. Median LVEF was 26 % (IQR 22%-35%). Inotropes were used in 518 (70.3%) patients. In 431 (83.2%) patients, a single inotrope was administered. Inotropic therapy was associated with higher risk of in-hospital death/urgent heart transplant (OR=10.628, 95% CI 5.055 to 22.344, p<0.001). At 180-day follow-up, of the 431 patients discharged home, 39 (9.0%) died, 21 (4.9%) underwent transplantation and 183 (42.4%) were readmitted. Inotropes were not associated with outcome (death, transplant and rehospitalisation) after discharge. Conclusions Inotropic drugs are still widely used in patients with advanced decompensated HF and are associated with a worse in-hospital prognosis. In contrast with previous results, intermittent use of inotropes during hospitalisation did not determine a worse prognosis at 180-day follow-up. These data may add to prognostic evaluation in patients with advanced HF in centres where mechanical circulatory support is not broadly available.
Palavras-chave
Referências
- Abraham WT, 2005, J AM COLL CARDIOL, V46, P57, DOI 10.1016/j.jacc.2005.03.051
- Arora S, 2017, AM J CARDIOL, V120, P616, DOI 10.1016/j.amjcard.2017.05.028
- Constantinescu AA, 2014, EUR J HEART FAIL, V16, P435, DOI 10.1002/ejhf.39
- Cuffe MS, 2002, JAMA-J AM MED ASSOC, V287, P1541, DOI 10.1001/jama.287.12.1541
- Elkayam U, 2007, AM HEART J, V153, P98, DOI 10.1016/j.ahj.2006.09.005
- Follath F, 2011, INTENS CARE MED, V37, P619, DOI 10.1007/s00134-010-2113-0
- Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217
- Hashim T, 2015, CIRC-HEART FAIL, V8, P880, DOI 10.1161/CIRCHEARTFAILURE.114.001778
- Kalogeropoulos AP, 2014, J CARD FAIL, V20, P593, DOI 10.1016/j.cardfail.2014.05.006
- King JB, 2017, PHARMACOTHERAPY, V37, P662, DOI 10.1002/phar.1939
- Mebazaa A, 2011, INTENS CARE MED, V37, P290, DOI 10.1007/s00134-010-2073-4
- Mortara A, 2014, J HEART LUNG TRANSPL, V33, P1056, DOI 10.1016/j.healun.2014.05.015
- Nieminen MS, 2006, EUR HEART J, V27, P2725, DOI 10.1093/eurheartj/ehl193
- Nohria A, 2003, J AM COLL CARDIOL, V41, P1797, DOI 10.1016/S0375-1097(03)00309-7
- Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI [10.1093/eurheartj/ehw128, 10.1002/ejhf.592]
- Terhoch CB, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006207
- von Scheidt W, 2016, CLIN RES CARDIOL, V105, P471, DOI 10.1007/s00392-016-0968-y